KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Receivables (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 12 years of Receivables data on record, last reported at $51.8 million in Q4 2025.

  • For Q4 2025, Receivables rose 24.39% year-over-year to $51.8 million; the TTM value through Dec 2025 reached $51.8 million, up 24.39%, while the annual FY2025 figure was $51.8 million, 24.39% up from the prior year.
  • Receivables reached $51.8 million in Q4 2025 per RIGL's latest filing, up from $46.0 million in the prior quarter.
  • Across five years, Receivables topped out at $142.2 million in Q1 2021 and bottomed at $3.1 million in Q1 2025.
  • Average Receivables over 5 years is $31.6 million, with a median of $25.5 million recorded in 2023.
  • Peak YoY movement for Receivables: surged 1372.0% in 2021, then tumbled 89.28% in 2022.
  • A 5-year view of Receivables shows it stood at $15.5 million in 2021, then rose by 29.27% to $20.0 million in 2022, then skyrocketed by 52.75% to $30.6 million in 2023, then soared by 36.22% to $41.6 million in 2024, then grew by 24.39% to $51.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $51.8 million in Q4 2025, $46.0 million in Q3 2025, and $40.0 million in Q2 2025.